The construction of SK Plasma's blood product factory, currently underway in Indonesia, will receive full support through a joint declaration by the governments of both countries.
SK Plasma announced on the 24th that Kim Seung-joo, CEO of SK Plasma, announced a joint declaration for the construction and operation of the Indonesian blood product factory at an event held by Cho Kyu-hong, Minister of Health and Welfare of Korea, and Budi Gunadi Sadikin, Minister of Health of Indonesia, commemorating the 50th anniversary of diplomatic relations between Korea and Indonesia.
At the event held at the Ambassador Pullman Hotel in Jung-gu, Seoul, Minister Cho, Minister Budi, and Luhut Panjaitan, Indonesian Coordinating Minister for Maritime and Investment Affairs, discussed the achievements of health and medical cooperation between the two countries. Afterwards, in the presence of Ministers Cho and Budi, Kim Seung-joo, CEO of SK Plasma, and Andrianto Dernatra, Director of Daewoong Infion, announced the joint declaration, securing full support and cooperation for SK Plasma’s construction and operation of the Indonesian blood product factory. Daewoong Infion is a joint venture established in 2012 by Daewoong Pharmaceutical and the Indonesian company Infion.
Minister Budi stated, “The Indonesian government is striving to build a resilient healthcare system at the national level,” and added, “Today’s occasion is the result of continuous efforts by the governments and private companies of both countries, and I hope that through steady communication, both countries can develop together.”
On the 8th, SK Plasma received final approval from the Indonesian Ministry of Health to construct the SK Plasma blood product factory near Jakarta, Indonesia. Construction is scheduled to begin in May, aiming for completion by mid-2025. The facility will be capable of processing 1 million liters of plasma raw material annually.
A bird's-eye view of the local blood product factory of SK Plasma, scheduled to be built near Jakarta, Indonesia [Photo by SK Plasma]
The company explained that once the factory is completed, it will operate locally and transfer blood product manufacturing and equipment technology and know-how, which is expected to bring Indonesia one step closer to self-sufficiency in the pharmaceutical sector. In particular, this case is the first example where our government and private companies have achieved comprehensive project rights from a foreign government through cooperation in the bio-industry sector, covering contract manufacturing, technology export, engineering, procurement, and construction (EPC), and local operation.
CEO Kim Seung-joo said, “Under the full support of both governments, we will successfully carry out the construction and operation of the Indonesian blood product factory,” and added, “We will continue to export technology to countries that do not have plasma processing technology themselves, contributing to the advancement of global health care.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
